There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Theratechnologies (THTX – Research Report), MoonLake Immunotherapeutics (MLTX – Research Report) and DENTSPLY SIRONA (XRAY – Research Report) with bullish sentiments.
Theratechnologies (THTX)
In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Theratechnologies, with a price target of $3.00. The company’s shares closed last Thursday at $1.48.
According to TipRanks.com, Walsh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Theratechnologies is a Moderate Buy with an average price target of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
MoonLake Immunotherapeutics (MLTX)
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on MoonLake Immunotherapeutics today and set a price target of $75.00. The company’s shares closed last Thursday at $51.14.
According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MoonLake Immunotherapeutics with a $75.67 average price target, a 31.5% upside from current levels. In a report issued on February 14, Wolfe Research also initiated coverage with a Buy rating on the stock.
DENTSPLY SIRONA (XRAY)
In a report released today, David Saxon from Needham reiterated a Buy rating on DENTSPLY SIRONA, with a price target of $42.00. The company’s shares closed last Thursday at $32.57.
According to TipRanks.com, Saxon is a 4-star analyst with an average return of
DENTSPLY SIRONA has an analyst consensus of Moderate Buy, with a price target consensus of $37.86, a 10.6% upside from current levels. In a report issued on February 26, Leerink Partners also initiated coverage with a Buy rating on the stock with a $42.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on THTX:
- Theratechnologies Faces FDA Setback on Trogarzo
- Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
- Theratechnologies announces FDA RTF regarding sBLA for Trogarzo
- Theratechnologies price target lowered to $5 from $8 at Canaccord
- Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
